How to access Nucala from Egypt — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Egyptian patient with severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), or chronic rhinosinusitis with nasal polyps may receive a prescription for Nucala (mepolizumab) from their treating pulmonologist, allergist, rheumatologist, or ENT specialist. Nucala is FDA-approved in the United States and manufactured by GSK. It is a humanised monoclonal antibody that targets IL-5, reducing circulating eosinophils. Where Nucala is not on an Egyptian hospital formulary for the patient's specific indication, a named-patient import pathway via the Egyptian Drug Authority (EDA) is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Nucala is administered subcutaneously every 4 weeks. Dosing varies by indication — 100 mg for severe eosinophilic asthma, 300 mg for EGPA and HES. Your treating physician confirms eosinophil count, indication-specific criteria (exacerbation history for asthma; vasculitis activity for EGPA; persistent eosinophilia for HES), infection screening, and the monitoring plan per FDA labeling.
Is Nucala legally importable into Egypt?
Yes — through the Egyptian Drug Authority (EDA) named-patient / special-import framework. The pathway allows an Egypt-licensed physician to import a medicine not locally registered, or a specific dose form not stocked, when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative is suitable for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
For IL-5 biologics, EDA reviewers are familiar with the submission pattern, and Nucala-specific applications typically cite the indication-specific eosinophil-driven mechanism.
How the pathway works, step by step
- Consultation with your treating physician. Eosinophil count, indication-specific severity documentation, and clinical rationale.
- Pre-treatment screening. Infection and parasitic screening per labeling.
- EDA named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Cold-chain shipment. Nucala ships at 2–8°C with continuous temperature monitoring.
- Arrival and first dose. The dispensing facility releases product for in-clinic or at-home administration after training.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming the indication, eosinophil evidence, prior therapies, and Nucala as the indicated biologic
- Verification of their Egyptian medical registration
- Patient identifier
- Pre-treatment screening confirmation
- Planned monthly dosing schedule
Reserve Meds provides a physician documentation kit that bundles the templates EDA reviewers expect to see for IL-5-class biologics.
Costs and timing
Nucala's US cash-pay reference price for a single 100 mg dose sits in a broad indicative range of roughly USD 3,500–4,500; the 300 mg dose (three 100 mg injections or the dedicated 300 mg kit for EGPA/HES) is priced proportionally higher. International cold-chain logistics, EDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted and customs processing begins. Maintenance doses ship on a rolling basis.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Nucala specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for EDA / customs review.
- Logistics. Cold-chain, temperature-monitored, internationally tracked shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in Egypt? Yes, when executed through the EDA named-patient framework with appropriate documentation.
What if another IL-5 biologic is available locally? Your physician will consider locally registered alternatives. Named-patient rationale applies where Nucala specifically fits the indication (for example, EGPA, HES) and where the locally registered option does not.
Can Nucala be self-injected? Yes, the pre-filled pen and auto-injector forms are designed for patient or caregiver self-injection after clinic training.
Will private insurance cover this? Cash-pay is the default. Some Egyptian insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Nucala coordination in Egypt.
Add me to the Nucala waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.